NFX1-123 and human papillomavirus 16E6 increase notch expression in keratinocytes

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13741-13750

  Vliet Gregg, Portia A ^a   Hamilton, Jennifer R ^a   Katzenellenbogen, Rachel A ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MESSENGER RNA; NOTCH1 RECEPTOR; PROTEIN E6; PROTEIN NFX1 123; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

16E6 GENE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INTERACTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MICROARRAY ANALYSIS; NFX1 123 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; UPREGULATION; VIRUS CELL INTERACTION; WART VIRUS;

CELLS, CULTURED; HUMAN PAPILLOMAVIRUS 16; HUMANS; INFANT, NEWBORN; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, NOTCH1; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TELOMERASE; UP-REGULATION;

EID: 84888023302     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02582-13     Document Type: Article

References (53)

1. Munoz N, Bosch FX, de Tafur SSL, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, Gonzalez LC, Kaldor JM, Guerrero E, Lorincz A, Santamaria M, Alonso De Ruiz P, Aristizabal N, Shah K. 1992. The causal link between human papillomavirus and invasive cervical cancer:a population-based case-control study in Colombia and Spain. Int. J. Cancer 52:743-749.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papilloma-virus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
3. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX. 2010. Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048-1056.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29:4294-4301.
5. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92:709-720.
6. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356:1944-1956.
7. Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC, Porter P, Daling JR, McDougall JK, Galloway DA. 2001. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 61:1934-1940.
8. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN. 2005. Penile cancer:importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int. J. Cancer 116:606-616.
9. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H. 2002. A population-based study of squamous cell vaginal cancer:HPV and cofactors. Gynecol. Oncol. 84:263-270.
10. Gross G, Pfister H. 2004. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med. Microbiol. Immunol. 193:35-44.
11. Salit IE, Tinmouth J, Chong S, Raboud J, Diong C, Su D, Sano M, Lytwyn A, Chapman W, Mahony J. 2009. Screening for HIV-associated anal cancer:correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol. Biomarkers Prev. 18:1986-1992.
12. Howie HL, Katzenellenbogen RA, Galloway DA. 2009. Papillomavirus E6 proteins. Virology 384:324-334.
13. Talis AL, Huibregtse JM, Howley PM. 1998. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:6439-6445.
14. Nakagawa S, Huibregtse JM. 2000. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20:8244-8253.
15. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. 2005. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79:3737-3747.
16. Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, Tomaic V, Kelley ML, Baker CC, Huibregtse J, Schlegel R. 2005. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 280:10807-10816.
17. Handa K, Yugawa T, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. 2007. E6AP-dependent degradation of DLG4/PSD95 by high-risk human papillomavirus type 18 E6 protein. J. Virol. 81:1379-1389.
18. Shai A, Pitot HC, Lambert PF. 2010. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 70:5064-5073.
19. Kuballa P, Matentzoglu K, Scheffner M. 2007. The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J. Biol. Chem. 282:65-71.
20. Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafken PR, Galloway DA. 2007. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16E6 expressing cells. J. Virol. 81:3786-3796. doi:10.1128/JVI.02007-06.
21. Katzenellenbogen RA, Vliet-Gregg P, Xu M, Galloway DA. 2009. NFX1-123 increases hTERT expression and telomerase activity posttranscriptionally in human papillomavirus type 16 E6 keratinocytes. J. Virol. 83:6446-6456.
22. Gewin L, Myers H, Kiyono T, Galloway DA. 2004. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18:2269-2282.
23. Xu M, Luo W, Elzi DJ, Grandori C, Galloway DA. 2008. NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes. Mol. Cell. Biol. 28:4819-4828.
24. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjanen S, Favalli C, Syrjanen K. 2006. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. Diagn. Cytopathol. 34:739-748.
25. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. 1998. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84-88.
26. Lambertini C, Pantano S, Dotto GP. 2010. Differential control of Notch1 gene transcription by Klf4 and Sp3 transcription factors in normal versus cancer-derived keratinocytes. PLoS One 5:e10369. doi:10.1371/journal.pone.0010369.
27. Yugawa T, Narisawa-Saito M, Yoshimatsu Y, Haga K, Ohno S, Egawa N, Fujita M, Kiyono T. 2010. DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. Cancer Res. 70:4034-4044.
28. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. 2007. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell. Biol. 27:3732-3742.
29. Talora C, Sgroi DC, Crum CP, Dotto GP. 2002. Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 16:2252-2263.
30. Rangarajan A, Syal R, Selvarajah S, Chakrabarti O, Sarin A, Krishna S. 2001. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology 286:23-30.
31. Lathion S, Schaper J, Beard P, Raj K. 2003. Notch1 can contribute to viral-induced transformation of primary human keratinocytes. Cancer Res. 63:8687-8694.
32. Bajaj J, Maliekal TT, Vivien E, Pattabiraman C, Srivastava S, Krishnamurthy H, Giri V, Subramanyam D, Krishna S. 2011. Notch signaling in CD66+ cells drives the progression of human cervical cancers. Cancer Res. 71:4888-4897.
33. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. 2003. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell Physiol. 194:356-362.
34. Henken FE, De-Castro AJ, Rosl F, Bosch L, Meijer CJ, Snijders PJ, Steenbergen RD. 2012. The functional role of Notch signaling in HPVmediated transformation is dose-dependent and linked to AP-1 alterations. Cell Oncol. 35:77-84.
35. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. 1995. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. U.S.A. 92:6414-6418.
36. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Munger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487:491-495.
37. Bartz SR, Vodicka MA. 1997. Production of high-titer human immuno-deficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12:337-342.
38. Borggrefe T, Oswald F. 2009. The Notch signaling pathway:transcriptional regulation at Notch target genes. Cell Mol. Life Sci. 66:1631-1646.
39. Kozlov G, Menade M, Rosenauer A, Nguyen L, Gehring K. 2010. Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein. J. Mol. Biol. 397:397-407.
40. Grishin NV. 1998. The R3H motif:a domain that binds single-stranded nucleic acids. Trends Biochem. Sci. 23:329-330.
41. Lisso J, Altmann T, Mussig C. 2006. The AtNFXL1 gene encodes a NF-X1 type zinc finger protein required for growth under salt stress. FEBS Lett. 580:4851-4856.
42. Stroumbakis ND, Li Z, Tolias PP. 1996. A homolog of human transcription factor NF-X1 encoded by the Drosophila shuttle craft gene is required in the embryonic central nervous system. Mol. Cell. Biol. 16:192-201.
43. Song Z, Krishna S, Thanos D, Strominger JL, Ono SJ. 1994. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J. Exp. Med. 180:1763-1774.
44. Pasyukova EG, Roshina NV, Mackay TF. 2004. Shuttle craft:a candidate quantitative trait gene for Drosophila lifespan. Aging Cell 3:297-307.
45. Kunz J, Loeschmann A, Deuter-Reinhard M, Hall MN. 2000. FAP1, a homologue of human transcription factor NF-X1, competes with rapamycin for binding to FKBP12 in yeast. Mol. Microbiol. 37:1480-1493.
46. Arlotta P, Miyazaki D, Copeland NG, Gilbert DJ, Jenkins NA, Ono SJ. 2002. Murine NFX.1:isolation and characterization of its messenger RNA, mapping of its chromosomal location and assessment of its developmental expression. Immunology 106:173-181.
47. Mussig C, Schroder F, Usadel B, Lisso J. 2010. Structure and putative function of NFX1-like proteins in plants. Plant Biol. 12:381-394.
48. Tolias PP, Stroumbakis ND. 1998. The Drosophila zygotic lethal gene shuttle craft is required maternally for proper embryonic development. Dev. Genes Evol. 208:274-282.
49. Asano T, Masuda D, Yasuda M, Nakashita H, Kudo T, Kimura M, Yamaguchi K, Nishiuchi T. 2008. AtNFXL1, an Arabidopsis homologue of the human transcription factor NF-X1, functions as a negative regulator of the trichothecene phytotoxin-induced defense response. Plant J. 53:450-464.
50. Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. 2012. Cutaneous beta-human papillomavirus E6 proteins bind Mastermindlike coactivators and repress Notch signaling. Proc. Natl. Acad. Sci. U.S.A. 109:E1473-E1480.
51. Brimer N, Lyons C, Wallberg AE, Vande Pol SB. 2012. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene 31:4639-4646.
52. Meyers JM, Spangle JM, Munger K. 2013. The HPV8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J. Virol. 87:4762-4767.
53. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J. Virol. 86:13174-13186.